Active Pharmaceutical Ingredient CAS 37319 17 8 Pentosan Polysulphate Sodium(PPS)

Product Overview

Description

Pentosan Polysulphate Sodium(PPS)

 

 

Product Name: Pentosan Polysulphate Sodium(PPS)

Type: Urinary System Agents

Purity: 99%min

Brand: PIONEER

MW: 1705.06472

ME: C29H38Na10O50S9

Apperance: White Powder

 

 

ANALYSIS	SPECIFICATION	RESULTS
Appearance	Brown yellow powder	Complies
Odor	Characteristic	Complies
Extract Ratio	10:1	Complies
Sieve analysis	NLT 95% pass 80 mesh	Complies
Loss on Drying	≤5.0%	2.5%
Residue on Ignition	≤3.0%	2.16%
Heavy Metal	<10ppm	Complies
Assay	<2ppm	Complies
Residual Solvents	Eur.Pharm.	Complies
Microbiology
Total Plate Count	<1000cfu/g	380cfu/g
Yeast & Moulds	<100cfu/g	20cfu/g
E.Coli	Negative	Complies
Salmonella	Negative	Complies
Conclusion	Conform with specification

 

 

Pentosan polysulfate preserves renal autoregulation in ANG II-infused hypertensive rats. Angiotensin II hypertension antiinflammatory.

Interstitial cystitis/painful bladder syndrome (IC/PBS) is a condition where patients struggle with symptoms of urinary frequency, urgency, pressure and/or pain, as well as nocturia (frequent urination at night), dyspareunia (painful intercourse), pain and/or discomfort while sitting in a car, while driving and/or traveling. Elmiron is available as pills or as a direct infusion into the bladder.
The sodium salt of PPS has low bioavailability when taken orally. Research presented in 2005 by Alza Pharmaceuticals demonstrated that 94% of the medication was excreted, intact, in faeces. This means that 6% was excreted through urine and in contact with the bladder. It appears to be most effective when taken for several months. More recently, PPS has been studied as part of a "rescue instillation" which is placed directly in the bladder and can, perhaps, provide better effectiveness. Research presented in 2005 showed PPS had 90% effectiveness in reducing the symptoms of IC/PBS patients by using this instillation.